Wegovy
-
healthGLP-1 Users Reduce Physical Activity Despite Muscle Loss Risks
New research presented at ENDO 2026 reveals GLP-1 users significantly decrease exercise, risking lean muscle mass. Experts emphasize mandatory resistance training and clinical oversight for safe weight management.
-
healthGLP-1 Drugs Linked to Lower Breast Cancer Risk and Better Outcomes
Observational studies show GLP-1 meds like Ozempic may reduce breast cancer incidence by 30% and improve survival rates.
-
healthGLP-1 Drugs Like Ozempic Show Broad Cancer Protection Promise
Multiple studies at ASCO 2024 show GLP-1 drugs reduce cancer risk and improve outcomes across tumor types, with potential benefits tied to inflammation reduction and weight loss.
-
healthExercise Boosts Ozempic Benefits, Preserves Muscle in Obesity Study
New research at EAS 2026 shows combining semaglutide with exercise preserves muscle and enhances fat loss.
-
healthGLP-1 Drug Weight Loss Linked to Lower Disease Risk
New study finds significant weight loss from GLP-1 drugs like Ozempic reduces risk of obesity-related conditions including sleep apnea and kidney disease.
-
healthFrance Becomes First EU Country to Reimburse Weight-Loss Drugs
France will start covering costs of Wegovy and Mounjaro from June 15, a historic move making it the first EU nation to offer permanent reimbursement for GLP-1 weight-loss medications.
-
healthWeight Loss Drugs Linked to Hidden Social Stigma, Study Finds
New research reveals GLP-1 drug users face harsher judgment than those losing weight through diet and exercise.
-
healthOzempic Breath: The Unsettling Keto-Like Side Effect Patients Are Reporting
Patients taking GLP-1 drugs report 'fishy' bad breath known as Ozempic breath. Experts discuss dehydration as the likely cause.